Product Information
SULFASALAZINE DR 500 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.2859 per EA under NDC 59762010406. Its NADAC has been published 337 times since Apr 22, 2020.
FDA first approved this application before 1982. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Sulfasalazine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
500 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762010406
Classification
Generic
Dosage Form
TABLET, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SULFASALAZINEApproval Type
Authorized Generic (NDA)
FDA Application
NDA007073FDA Approved
Before 1982
TE Code
AB
On Market Since
5/5/2005
Pharmacological Classes
Price Statistics
The NADAC for SULFASALAZINE DR 500 MG TAB has been published 337 times since Apr 22, 2020, and over the history we have for it it has risen 33.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2859 per EA |
|---|---|
| All-time high | $0.2859 (Sep 30, 2026) |
| All-time low | $0.1470 (Jul 17, 2024) |
| 52-week high | $0.2859 |
| 52-week low | $0.2514 |
| Median price | $0.2384 |
| Average price | $0.2396 |
| Largest weekly change | +40.9% (Aug 28, 2024) |
| Weeks tracked | 337 |
| Tracking since | Apr 22, 2020 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 30% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Sulfasalazine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SULFASALAZINE DR 500 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for SULFASALAZINE DR 500 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $0.2859 per EA (NDC 59762010406), effective Sep 30, 2026.
How has the price of SULFASALAZINE DR 500 MG TAB changed over time?
Over the history we have for it, the NADAC for SULFASALAZINE DR 500 MG TAB has risen 33.5%. It has been tracked across 337 weekly CMS publications since Apr 22, 2020.
What are the highest and lowest recorded NADAC prices for SULFASALAZINE DR 500 MG TAB?
Since Apr 22, 2020, the NADAC for SULFASALAZINE DR 500 MG TAB has ranged from a low of $0.1470 (Jul 17, 2024) to a high of $0.2859 (Sep 30, 2026), with a median of $0.2384 per EA.
Are there cheaper alternatives to SULFASALAZINE DR 500 MG TAB?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, SULFASALAZINE 500 MG TABLET, is $0.1991 per EA — about 30% below SULFASALAZINE DR 500 MG TAB.
Who manufactures SULFASALAZINE DR 500 MG TAB?
SULFASALAZINE DR 500 MG TAB (NDC 59762010406) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.